Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $39 | $38 | $42 | $34 |
| Short-Term Investments | $242 | $266 | $291 | $337 |
| Receivables | $0 | $0 | $0 | $5 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $8 | $8 | $10 | $10 |
| Total Curr. Assets | $288 | $312 | $343 | $386 |
| Property Plant & Equip (Net) | $33 | $34 | $35 | $37 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $6 | $6 | $6 | $7 |
| Total NC Assets | $39 | $40 | $41 | $44 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $327 | $352 | $384 | $430 |
| Liabilities | – | – | – | – |
| Payables | $7 | $4 | $8 | $7 |
| Short-Term Debt | $0 | $0 | $0 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $30 | $35 | $42 | $42 |
| Total Curr. Liab. | $37 | $39 | $49 | $53 |
| LT Debt | $37 | $38 | $39 | $40 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $1 | $1 | $1 | $1 |
| Total NC Liab. | $37 | $38 | $39 | $40 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $37 | $38 | $39 | $43 |
| Total Liabilities | $74 | $77 | $89 | $93 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,156 | -$1,130 | -$1,103 | -$1,054 |
| AOCI | $0 | $0 | $0 | $1 |
| Other Equity | $1,409 | $1,404 | $1,398 | $1,391 |
| Total Equity | $253 | $274 | $295 | $337 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $327 | $352 | $384 | $430 |
| Net Debt | -$2 | $0 | -$3 | $9 |